COPD pp 211-217 | Cite as

Prevention of COPD

  • HyoungKyu YoonEmail author


Chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and lungs to noxious particles or gases [1]. Chronic airway inflammation, which is a pathogenic mechanism of COPD, is caused by gene–environment interactions. Although the genetic factors contributing to gene–environment interactions cannot be controlled, COPD can be prevented if the environmental risk factors are eliminated. COPD prevention is more important than treatment because it is almost impossible to lung function normalization after airflow limitation occurs in COPD.


  1. 1.
    Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.CrossRefGoogle Scholar
  2. 2.
    Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30(5):993–1013.CrossRefGoogle Scholar
  3. 3.
    Zeng G, Sun B, Zhong N. Non-smoking-related chronic obstructive pulmonary disease: a neglected entity? Respirology. 2012;17(6):908–12.CrossRefGoogle Scholar
  4. 4.
    Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, et al. Not 15 but 50% of smokers develop COPD?—report from the obstructive lung disease in northern Sweden studies. Respir Med. 2003;97(2):115–22.CrossRefGoogle Scholar
  5. 5.
    Tonnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013;22(127):37–43.CrossRefGoogle Scholar
  6. 6.
    Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.PubMedGoogle Scholar
  7. 7.
    Tashkin DP, Murray RP. Smoking cessation in chronic obstructive pulmonary disease. Respir Med. 2009;103(7):963–74.CrossRefGoogle Scholar
  8. 8.
    Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.Google Scholar
  9. 9.
    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.Google Scholar
  10. 10.
    McDonald CF, Khor Y. Advances in chronic obstructive pulmonary disease. Intern Med J. 2013;43(8):854–62.CrossRefGoogle Scholar
  11. 11.
    Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598–600.CrossRefGoogle Scholar
  12. 12.
    Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–43.CrossRefGoogle Scholar
  13. 13.
    Rojas-Martinez R, Perez-Padilla R, Olaiz-Fernandez G, Mendoza-Alvarado L, Moreno-Macias H, Fortoul T, et al. Lung function growth in children with long-term exposure to air pollutants in Mexico City. Am J Respir Crit Care Med. 2007;176(4):377–84.CrossRefGoogle Scholar
  14. 14.
    Gauderman WJ, Avol E, Gilliland F, Vora H, Thomas D, Berhane K, et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med. 2004;351(11):1057–67.CrossRefGoogle Scholar
  15. 15.
    Laumbach RJ. Outdoor air pollutants and patient health. Am Fam Physician. 2010;81(2):175–80.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Fishwick D, Sen D, Barber C, Bradshaw L, Robinson E, Sumner J, et al. Occupational chronic obstructive pulmonary disease: a standard of care. Occup Med (Lond). 2015;65(4):270–82.CrossRefGoogle Scholar
  17. 17.
    Hanson C, Rutten EP, Wouters EF, Rennard S. Influence of diet and obesity on COPD development and outcomes. Int J Chron Obstruct Pulmon Dis. 2014;9:723–33.CrossRefGoogle Scholar
  18. 18.
    Duijts L, Reiss IK, Brusselle G, de Jongste JC. Early origins of chronic obstructive lung diseases across the life course. Eur J Epidemiol. 2014;29(12):871–85.CrossRefGoogle Scholar
  19. 19.
    Neuman A, Hohmann C, Orsini N, Pershagen G, Eller E, Kjaer HF, et al. Maternal smoking in pregnancy and asthma in preschool children: a pooled analysis of eight birth cohorts. Am J Respir Crit Care Med. 2012;186(10):1037–43.CrossRefGoogle Scholar
  20. 20.
    Stocks J, Sonnappa S. Early life influences on the development of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2013;7(3):161–73.CrossRefGoogle Scholar
  21. 21.
    Jagana R, Bartter T, Joshi M. Delay in diagnosis of chronic obstructive pulmonary disease: reasons and solutions. Curr Opin Pulm Med. 2015;21(2):121–6.CrossRefGoogle Scholar
  22. 22.
    Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497–505.CrossRefGoogle Scholar
  23. 23.
    Bednarek M, Gorecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipczyk G, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax. 2006;61(10):869–73.CrossRefGoogle Scholar
  24. 24.
    Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The lung health study. Am J Respir Crit Care Med. 2000;161(2 Pt 1):381–90.CrossRefGoogle Scholar
  25. 25.
    Stratelis G, Molstad S, Jakobsson P, Zetterstrom O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care. 2006;24(3):133–9.CrossRefGoogle Scholar
  26. 26.
    Simmons MS, Connett JE, Nides MA, Lindgren PG, Kleerup EC, Murray RP, et al. Smoking reduction and the rate of decline in FEV(1): results from the lung health study. Eur Respir J. 2005;25(6):1011–7.CrossRefGoogle Scholar
  27. 27.
    Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–9.CrossRefGoogle Scholar
  28. 28.
    Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8.CrossRefGoogle Scholar
  29. 29.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–8.CrossRefGoogle Scholar
  30. 30.
    Rennard SI, Drummond MB. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet. 2015;385(9979):1778–88.CrossRefGoogle Scholar
  31. 31.
    Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;1:CD002733.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Yeouido St. Mary’s Hospital, The Catholic University of KoreaSeoulSouth Korea

Personalised recommendations